Pyxis Oncology (NASDAQ:PYXS) Lowered to Sell Rating by Wall Street Zen

Pyxis Oncology (NASDAQ:PYXS) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

A number of other research analysts also recently issued reports on the stock. Stifel Nicolaus started coverage on shares of Pyxis Oncology in a research report on Monday, November 3rd. They issued a “buy” rating and a $9.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Pyxis Oncology in a report on Wednesday, October 8th. Zacks Research cut shares of Pyxis Oncology from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 4th. HC Wainwright lifted their price objective on Pyxis Oncology from $5.00 to $7.00 and gave the stock a “buy” rating in a research report on Friday. Finally, Stephens boosted their price objective on Pyxis Oncology from $5.00 to $8.00 and gave the company an “overweight” rating in a research note on Monday, November 24th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $7.20.

Pyxis Oncology Trading Down 26.3%

Shares of PYXS stock opened at $1.28 on Friday. Pyxis Oncology has a 1-year low of $0.83 and a 1-year high of $5.55. The stock has a market cap of $79.38 million, a price-to-earnings ratio of -0.80 and a beta of 1.37. The stock has a 50-day moving average of $4.01 and a 200-day moving average of $2.38.

Pyxis Oncology (NASDAQ:PYXS) last posted its quarterly earnings data on Monday, November 3rd. The company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.01. Sell-side analysts forecast that Pyxis Oncology will post -1.04 earnings per share for the current year.

Institutional Investors Weigh In On Pyxis Oncology

A number of hedge funds have recently added to or reduced their stakes in the company. Catalyst Funds Management Pty Ltd acquired a new position in shares of Pyxis Oncology during the second quarter worth approximately $26,000. Kingstone Capital Partners Texas LLC bought a new stake in Pyxis Oncology during the 2nd quarter valued at $37,000. Persistent Asset Partners Ltd acquired a new position in Pyxis Oncology during the third quarter worth $77,000. XTX Topco Ltd acquired a new position in Pyxis Oncology during the second quarter worth $40,000. Finally, Velan Capital Investment Management LP bought a new position in shares of Pyxis Oncology in the second quarter valued at $44,000. Institutional investors and hedge funds own 39.09% of the company’s stock.

Pyxis Oncology Company Profile

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.